RESUMO
Background: Acute kidney injury (AKI) poses a significant morbidity and mortality risk to critically ill COVID-19 patients. The aim of this study was to investigate the incidence, predictors, and outcomes of AKI in patients admitted to the intensive care unit (ICU) with critically ill COVID-19 pneumonia. Methods: A multicenter retrospective study in Saudi Arabia of adult patients aged at least 18 years diagnosed with COVID-19 pneumonia and admitted to the intensive care unit between May 2020 and May 2021 was conducted. The occurrence of AKI and associated risk factors, the need for continous renal replacement therapy (CRRT), and the outcome were reported. Results: The study included 340 patients admitted to the ICU with COVID-19. Their mean age was 66.7±13.4 years, ranging from 49 to 84 years, and most of them were men (63.8%). The most common concomitant diseases were hypertension (71.5%), diabetes (62.4%), IHD (37.6%), CKD (20%), heart failure (19.4%), and 81.2% suffered from ARDS. AKI occurred in 60.3% of patients, 38% were stage 1, 16.6% were stage 2, and 45.4% were stage 3. Approximately, 39% of patients required CRRT, out of which 76.2% were stage 3, which was significantly higher than the other stages (p<0.001). AKI patients suffered significantly from asthma and had lower levels of C-reactive protein (CRP), ferritin, lactate dehydrogenase (LDH), and blood urea nitrogen (BUN) and higher creatinine levels than patients without AKI (p<0.05 all). The overall mortality rate was 39.4%, and the mortality rate was significantly higher in patients with AKI than in patients without AKI (48.3% versus 25.9%; p<0.001). Conclusion: AKI is common in adults admitted to the ICU with COVID-19 and is associated with an increased risk of death. Early detection of AKI and appropriate treatment can positively impact COVID-19 outcome. CRRT is the preferred dialysis method in critically ill ICU patients with AKI.
RESUMO
Objetivo del estudio: evaluar si la puntuación de Mallampati modificada (MMS) puede predecir la presencia y la gravedad del síndrome de apnea obstructiva del sueño (AOS) en un grupo de pacientes que roncaban y presentaban apnea en los hospitales universitarios de Al-Azhar, El Cairo, Egipto y el Hospital Almoosa, Alhasa, Arabia Saudita. Métodos: Se realizó un estudio retrospectivo de pacientes que roncaban y presentaron apnea remitidos a un laboratorio del sueño para el diagnóstico de AOS mediante polisomnograma completo durante la noche desde enero de 2017 a noviembre de 2020. Se utilizó el índice de apnea-hipopnea (IAH) para categorizar la gravedad apnea del sueño. Se registraron edad, sexo, SMM, índice de masa corporal (IMC), comorbilidades, sueño y parámetros de laboratorio. Además, se registraron exámenes completos de Otorrinolaringología, Neurología y Medicina Interna. Resultados: El estudio se realizó en 350 pacientes que cumplían los criterios de inclusión con una edad media de 51,3 ± 14,3 años con un rango de 14 a 81 años. Más de la mitad de ellos (58,6%) eran hombres, el IMC medio fue de 35,1 ± 8,8 kg / m2 y el MMS medio fue de 4,7 ± 1,6 con aproximadamente el 65% de los pacientes agrupados en clases III y IV. Se diagnosticó AOS (IAH> 5) en 278 (79,4%) pacientes. Significativamente, la AOS se detectó más entre los hombres, aquellos con mayor edad, IMC, MMS y aquellos con diabetes mellitus tipo 2 (DM2). Una evaluación adicional mostró una correlación positiva significativa entre el IMC y el MMS con la gravedad de la AOS (ρ = 0,23, P <0,001 y ρ = 0,36, P <0,001) respectivamente. Conclusión: MMS es una herramienta útil para predecir la presencia y la gravedad de la AOS en pacientes que roncan. El IMC y el sexo masculino son predictores independientes
Aim of the study: To assess if the modified Mallampati score (MMS) can predict the presence and the severity of obstructive sleep apnea syndrome (OSA) in a group of patients who had snoring and witnessed apnea from Al -Azhar university hospitals, Cairo, Egypt, and Almoosa Hospital, Alhasa, Saudi Arabia. Methods: A retrospective study was done for patients who had snoring and witnessed apnea referred to a sleep lab for the diagnosis of OSA by overnight full polysomnogram from January 2017 to November 2020. Apnea-hypopnea index (AHI) was used to categorize the severity of sleep apnea. Age, sex, MMS, body mass index (BMI), comorbidities, sleep and laboratory parameters were recorded. Also, full Otorhinolaryngological, Neurological and Internal medicine examinations were recorded. Results: The study was carried out on 350 patients fulfilling the inclusion criteria with a mean age 51.3 ± 14.3 years ranging from 14 to 81 years. More than half of them (58.6%) were males, the mean BMI was 35.1 ± 8.8 kg/m2 and the mean MMS was 4.7 ± 1.6 with about 65% of patients grouped in classes III and IV. OSA (AHI>5) was diagnosed in 278 (79.4%) patients. Significantly, OSA was more detected among males, those with increased age, BMI, MMS, and those with type 2 diabetes mellitus (T2DM). Further evaluation showed a significant positive correlation between both BMI and MMS with the severity of OSA (ρ =0.23, P<0.001 and ρ =0.36, P<0.001) respectively. Conclusion: MMS is a useful tool to predict the presence as well as the severity of OSA in snoring patients. BMI and male gender are independent predictors
